GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for rare cancers: new immunotherapy combo trial launches
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in 154 people with five types of rare advanced cancers that have stopped responding to standard treatments. The goal is to see if this treatment can control the cancer for at least 24 weeks.…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
New hope for gut cancer patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that have grown after prior treatment with a standard radioactive therapy. The goal is to see if RYZ101 can slow tumor growth better than other available treatments. Abo…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Radioactive drug RYZ401 targets Hard-to-Treat tumors in first human trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Radioactive therapy plus surgery: a new hope for neuroendocrine cancer patients?
Disease control Recruiting nowThis early-phase study is testing whether giving a radioactive drug (Lutathera) before and after surgery can safely improve outcomes for people with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). About 10 participants with low- or intermediate-grade tumors th…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New Alpha-Particle therapy shows promise for Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new treatment called [212Pb]VMT-α-NET for people with advanced tumors that have a specific marker (SSTR2). The treatment delivers targeted radiation to kill cancer cells while sparing healthy tissue. The study involves up to 300 adults with neuroendocrine tumor…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for neuroendocrine tumors: PRRT under the microscope
Disease control Recruiting nowThis study looks at how well peptide receptor radionuclide therapy (PRRT) works for people with neuroendocrine tumors that started in the stomach, intestines, or pancreas. Researchers will track 50 patients to see how they respond to treatment, how long they live, and what side e…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Methodist Health System • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Could diet change the course of slow-growing gut tumors?
Knowledge-focused Recruiting nowThis study looks at whether nutrition is linked to better outcomes in adults with gastroenteropancreatic neuroendocrine tumors (NETs), a slow-growing cancer of the digestive system. Researchers will check 100 patients for signs of malnutrition and track their health over time. Th…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC
-
New study aims to predict who benefits from targeted radiation for rare gut tumors
Knowledge-focused Recruiting nowThis study is for people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are receiving a type of targeted radiation called PRRT. Researchers will use advanced PET-MRI scans and genetic tests to find early signs of whether the treatment is working. The go…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC